Abstracts tagged "rheumatoid arthritis"

Abstract Number: 419 • 2012 ACR/ARHP Annual Meeting
Epigenome Analysis of Rheumatoid Arthritis Synovial Fibroblasts Revealed TBX-5 As a Novel Transcription Factor in Chemokine Regulation
Emmanuel Karouzakis¹, Michelle Trenkmann², Renate E. Gay¹, Beat A. Michel¹, Steffen Gay¹ and Michel Neidhart¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland
Background/Purpose: Changes in DNA methylation and histone marks have been associated with diseases such as cancer, rheumatoid arthritis (RA) and systemic lupus erythematosus. Previously, we…
Abstract Number: 2343 • 2012 ACR/ARHP Annual Meeting
The Therapeutic Antibody Tregalizumab (BT-061) Induces Activation of Regulatory T Cells by Engaging a Unique CD4 Mediated Signaling That Strongly Differs From Signaling Events Induced by Standard Anti-CD4 Antibodies
Bianca Helling¹, Benjamin Daelken¹, Holger Wallmeier², Silke Aigner¹, Chantal Zuber¹, Martin Koenig¹, Andre Engling¹, Frank Osterroth¹, Niklas Czeloth³ and Christoph Uherek¹, ¹Biotest AG, Dreieich, Germany, ²Condor Scientific Computing & Consulting, Sulzbach, Germany, ³Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: The humanized CD4 specific monoclonal antibody (mAb) tregalizumab is currently being tested in phase II clinical trials in Rheumatoid Arthritis. In contrast to other…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 1187 • 2012 ACR/ARHP Annual Meeting
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity in Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Catriona Cramb¹, Jeremy Sokolove², Geoffrey M. Thiele³, Gail S. Kerr⁴, Grant W. Cannon⁵, Andreas M. Reimold⁶, Ted R. Mikuls⁷ and William H. Robinson⁸, ¹VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ²Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ³Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Smoking is a major risk factor for rheumatoid arthritis (RA) and has been associated with increased disease severity and lower rates disease remission. We…
Abstract Number: 375 • 2012 ACR/ARHP Annual Meeting
Cell Phone Based Automated Monitoring of Patients with Early Rheumatoid Arthritis
Kari Puolakka¹, Tuulikki Sokka² and Hannu Kautiainen³, ¹Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ²Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ³Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland
Cell phone based automated monitoring of patients with early rheumatoid arthritis Background/Purpose: Frequent monitoring improves patient compliance and outcomes of RA. Limited resources may hinder adherence…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 1662 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury
Kristine Kuhn¹, Hiroyuki Miyoshi², Nicholas A. Manieri², Nicole P. Malvin², Vinieth Bijanki², Paul Allen² and Thaddeus S. Stappenbeck², ¹Internal Medicine, Washington University School of Medicine, St. Louis, MO, ²Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Inhibition of IL-6 is used for treatment of rheumatoid arthritis and now being investigated as biologic therapy for a wide variety of autoimmune conditions,…
Abstract Number: 1014 • 2012 ACR/ARHP Annual Meeting
Trimmed Analyses, a New Approach to the Analysis of Sharp Score Data in the Assessment of Progression in Patients with Rheumatoid Arthritis
Robert B. M. Landewé¹, Désirée van der Heijde², Carol Connell³, John Bradley⁴, David Gruben³ and Michael Brown³, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the Phase 3 ORAL…
Abstract Number: 382 • 2012 ACR/ARHP Annual Meeting
Does Biased Risk Perception Explain the Underuse of Disease Modifying Anti-Rheumatic Drugs?
Richard W. Martin¹, Andrew J. Head², James D. Birmingham³ and Aaron T. Eggebeen¹, ¹Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ²Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ³Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: The prescription of a Disease Modifying Anti-rheumatic Drugs (DMARD) for patients with rheumatoid arthritis (RA) is considered a standard of effective care. However a…
Abstract Number: 2145 • 2012 ACR/ARHP Annual Meeting
Age At Onset Determines Severity and choice of Treatment in Early Rheumatoid Arthritis
Lena Innala¹, Bozena Möller², Lotta Ljung³, Torgny Smedby⁴, Anna Södergren⁵, Staffan Magnusson⁶, Ewa H. Berglin⁵, Solbritt M. Rantapää-Dahlqvist⁷ and Solveig Wållberg-Jonsson⁵, ¹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ²Department of Rheumatology, Sunderby Hospital, Luleå, Sweden, ³Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Rheumatology, Östersund hospital, Östersund, Sweden, ⁵Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁶Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden, ⁷Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA). Contributing factors are disease activity/severity and comorbidity. A relationship between age at onset and pharmacological treatment has…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting
Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Stephen Johnston¹, Tripthi Kamath², Nianwen Shi³, Robert Fowler³, Bong-Chul Chu³ and William Reiss⁴, ¹Truven Health Analytics, Bethesda, MD, ²Genentech, South San Francisco, CA, ³Truven Health Analytics, Washington, DC, ⁴Genentech Inc., South San Francisco, CA
Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].